Kymera Therapeutics’ (KYMR) Overweight Rating Reiterated at Stephens

Kymera Therapeutics (NASDAQ:KYMR)‘s stock had its “overweight” rating reaffirmed by equities researchers at Stephens in a research report issued on Tuesday,Benzinga reports. They presently have a $60.00 target price on the stock. Stephens’ target price would indicate a potential upside of 37.39% from the company’s previous close.

Other research analysts have also recently issued reports about the company. BTIG Research assumed coverage on Kymera Therapeutics in a research report on Tuesday, December 10th. They issued a “buy” rating and a $60.00 target price for the company. Wells Fargo & Company raised shares of Kymera Therapeutics from an “equal weight” rating to an “overweight” rating and upped their target price for the company from $38.00 to $57.00 in a research note on Monday, December 2nd. Leerink Partners reaffirmed an “outperform” rating and set a $60.00 price objective on shares of Kymera Therapeutics in a report on Friday, December 27th. Oppenheimer increased their target price on Kymera Therapeutics from $52.00 to $56.00 and gave the stock an “outperform” rating in a report on Friday, September 27th. Finally, Truist Financial restated a “buy” rating and set a $53.00 target price (down previously from $54.00) on shares of Kymera Therapeutics in a research report on Friday, November 1st. Three equities research analysts have rated the stock with a hold rating, thirteen have assigned a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, Kymera Therapeutics has a consensus rating of “Moderate Buy” and an average price target of $55.06.

Kymera Therapeutics Trading Up 7.5 %

Kymera Therapeutics stock traded up $3.06 on Tuesday, reaching $43.67. 123,180 shares of the stock were exchanged, compared to its average volume of 515,852. Kymera Therapeutics has a twelve month low of $27.47 and a twelve month high of $53.27. The firm has a fifty day moving average price of $42.83 and a two-hundred day moving average price of $44.56. The stock has a market cap of $2.83 billion, a PE ratio of -18.60 and a beta of 2.19.

Kymera Therapeutics (NASDAQ:KYMR) last announced its earnings results on Thursday, October 31st. The company reported ($0.82) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.83) by $0.01. Kymera Therapeutics had a negative net margin of 191.26% and a negative return on equity of 24.96%. The business had revenue of $3.74 million for the quarter, compared to analyst estimates of $10.34 million. During the same quarter in the previous year, the firm posted ($0.90) earnings per share. Kymera Therapeutics’s revenue was down 20.9% compared to the same quarter last year. Equities analysts anticipate that Kymera Therapeutics will post -2.79 EPS for the current fiscal year.

Insider Activity

In other Kymera Therapeutics news, insider Ellen Chiniara sold 3,129 shares of the company’s stock in a transaction on Monday, January 6th. The stock was sold at an average price of $41.75, for a total transaction of $130,635.75. Following the transaction, the insider now owns 54,826 shares of the company’s stock, valued at approximately $2,288,985.50. This represents a 5.40 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 15.82% of the stock is owned by insiders.

Institutional Investors Weigh In On Kymera Therapeutics

Institutional investors and hedge funds have recently made changes to their positions in the company. Massachusetts Financial Services Co. MA raised its position in shares of Kymera Therapeutics by 11.7% during the 3rd quarter. Massachusetts Financial Services Co. MA now owns 453,377 shares of the company’s stock valued at $21,458,000 after acquiring an additional 47,507 shares during the last quarter. Eventide Asset Management LLC increased its holdings in Kymera Therapeutics by 9.9% in the third quarter. Eventide Asset Management LLC now owns 507,902 shares of the company’s stock valued at $24,039,000 after purchasing an additional 45,803 shares during the last quarter. Renaissance Technologies LLC acquired a new position in Kymera Therapeutics in the second quarter valued at about $4,271,000. Intech Investment Management LLC bought a new position in Kymera Therapeutics during the third quarter worth about $650,000. Finally, JPMorgan Chase & Co. grew its position in shares of Kymera Therapeutics by 212.6% during the 3rd quarter. JPMorgan Chase & Co. now owns 140,491 shares of the company’s stock worth $6,649,000 after buying an additional 95,547 shares during the period.

Kymera Therapeutics Company Profile

Kymera Therapeutics, Inc, a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors.